{"prompt": "['Cara Therapeutics, Inc., CR845', 'IND 123140, SN 0072', 'Cara Therapeutics Inc.', 'Confidential', 'Page 67 of 92', 'CR845-CLIN3103', 'imputed using multiple calls of the SAS MI procedure using data from', 'patients within the same treatment group that have complete data at that time.', 'The proportion of patients who have an improvement from baseline with', 'respect to the weekly mean of the daily 24-hour Worst Itching Intensity NRS', 'score >3 points will be calculated for each imputed dataset', 'Similar to the primary analysis, results of the logistic regression on the', 'multiply imputed data sets will be summarized by the SAS MIANALYZE', 'procedure.', 'Sensitivity 3: (Tipping point analysis', 'Multiple imputation with mixed missing data mechanisms (MNAR for a missing', 'data pattern and MAR for others) will be used to assess the robustness of the', 'MAR assumption. This sensitivity analysis is to investigate the departure from', 'MAR assumption by progressively decreasing the treatment differences with', 'respect to the NRS scores over the missing visits in active treatment group until', 'conclusion from the primary analysis is overturned. The MI procedure includes', 'the following steps:', 'Uses MCMC methodology from PROC MI by treatment group to impute the', 'intermittent missing data to a monotone missing pattern', 'Uses a standard MAR-based MI approach from PROC MI to impute data from', 'monotone missing data', 'For patients in the active treatment group, shift parameter from PROC MI will', 'be progressively applied to impute the missing data, until the p-value >0.05', 'To evaluate the potential impact of the IA on the properties of statistical inference at the', 'end of the trial, the primary and sensitivity analyses of the primary endpoint will also be', 'presented separately for the sample of patients enrolled into the study after the IA.', '8.7.2', 'Secondary Efficacy Enppoints', 'The secondary efficacy endpoints are the:', 'Proportion of patients achieving >4-point improvement from baseline with respect', 'to the weekly mean of the daily 24-hour Worst Itching Intensity NRS at Week 12', '(Day 79 to 85) of the Double-blind Treatment Period;', 'Proportion of patients achieving >3-point improvement from baseline with respect', 'to the weekly mean of the daily 24-hour Worst Itching Intensity NRS at Week 8', 'of the Double-blind Treatment Period;', 'Proportion of patients achieving 3-point improvement from baseline with respect', 'to the weekly mean of the daily 24-hour Worst Itching Intensity NRS at Week 4', 'of the Double-blind Treatment Period;', '10 September 2019', 'Version 2.2']['Cara Therapeutics, Inc., CR845', 'IND 123140, SN 0072', 'Cara Therapeutics Inc.', 'Confidential', 'Page 68 of 92', 'CR845-CLIN3103', 'Proportion of patients achieving >4-point improvement from baseline with respect', 'to the weekly mean of the daily 24-hour Worst Itching Intensity NRS at Week 8', 'of the Double-blind Treatment Period;', 'Proportion of patients achieving >4-point improvement from baseline with respect', 'to the weekly mean of the daily 24-hour Worst Itching Intensity NRS at Week 4', 'of the Double-blind Treatment Period;', 'Change from baseline in itch-related quality of life at the end of Week 12 of the', 'Double-blind Treatment Period, as assessed by the Skindex-10 Scale total score;', 'Change from baseline in itch-related quality of life at the end of Week 12 of the', 'Double-blind Treatment Period, as assessed by the 5-D Itch Scale total score.', 'The proportion of patients achieving >4-point improvement from baseline at Week 12 of', 'the Double-blind Treatment Period, the proportion of patients achieving 3-point', 'improvement from baseline at Week 8 and Week 4, and the proportion of patients', 'achieving >4-point improvement from baseline at Week 8 and Week 4 with respect to the', 'weekly mean of the daily 24-hour Worst Itching Intensity NRS will be analyzed', 'following a methodology similar to the one employed for the primary analysis of the', 'primary endpoint.', 'The Skindex-10 Scale total score and the 5-D Itch Scale total score change from baseline', 'at Week 12 will be analyzed using an analysis of covariance (ANCOVA) model that will', 'contain treatment as fixed effect, with baseline score, region, and the randomization', 'stratification variables as covariates. The baseline 5-D total score and the Skindex-10', 'total score will be defined as the value collected on Day 1, prior to randomization.', 'For each domain in each questionnaire, missing values at Week 12 will be imputed using', 'an MI approach, assuming that patients who discontinue double-blind treatment early', 'would have similar domain scores as other patients in their respective treatment arm that', 'have complete data:', 'Intermittent missing scores will first be imputed using the Markov Chain Monte', 'Carlo (MCMC) method implemented with the SAS MI procedure, which is', 'appropriate for non-monotonic missing data;', 'The monotone missing values will then be multiply imputed with the SAS MI', 'procedure using the monotone regression method;', 'For each stage, MI will be performed within treatment group with covariates for', 'baseline score, region, both randomization stratification factors, and all non-', 'missing visit scores for each domain of the questionnaire;', 'For each questionnaire, the total score at each visit will be computed from the', 'domain scores for each imputed dataset;', '10 September 2019', 'Version 2.2']\n\n###\n\n", "completion": "END"}